| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/16/2008 | US7465715 e.g. N6-2-(4-aminophenyl)ethyladenosine (APNEA), N6-(4-amino-3-iodobenzyl)adenosine-5'-(N-methyluronamide) (AB-MECA), N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (IB-MECA), or 2-chloro-N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide; adenosine receptor agonist (A3RAg), adenylyl cyclase inhibitor |
| 12/16/2008 | US7465714 Inhibit the growth or proliferation of tumor cells in vitro and in vivo, cancer therapy or diagnosis, inhibits lung and/or colorectal cancer cell growth |
| 12/16/2008 | US7465713 human SGLT2 (sodium ion / glucose cotransporter 2) inhibitors; antidiabetic and hyperglycemic agents; obesity; 3-(6-O-ethoxycarbonyl- beta -D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methy]-1-isopropyl-5-methylpyrazole |
| 12/16/2008 | US7465712 Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
| 12/16/2008 | US7465553 Psoriasin expression by breast epithelial cells |
| 12/16/2008 | US7465549 incubating SV2 protein or fragment with levetiracetam or an analog or derivative thereof and a potential binding partner and determining if the potential binding partner modulates the binding of levetiracetam to the SV2 protein |
| 12/16/2008 | US7465541 Vitamin D3-responsive sequences located 5′-upstream of p27/kip 1 gene and methods of screening for pharmaceutical agents using the sequences |
| 12/16/2008 | US7465471 Use of a thio-functional acid such as 2-hydroxy-4-(methylthio)butanoic acid; fish food |
| 12/16/2008 | US7465466 Synergistic use of herba epimedii with at least three of fructus rosae laevigatae, fructus rubi, fructus psoralea, radix morindae officinalis, fructus schisandrac Chinensis, fructus ligustri lucidi, semen cuscutae and radix astragali |
| 12/16/2008 | US7465465 Mixture with chewing excipients; tablets |
| 12/16/2008 | US7465463 Topical applying; vision defects |
| 12/16/2008 | US7465462 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations |
| 12/16/2008 | US7465445 Methods of preventing or treating graft versus host reaction by administering an antibody or portion thereof that binds to AILIM |
| 12/16/2008 | US7465444 Methods of suppressing or treating an inflammatory bowel disease by administering an antibody or portion thereof that binds to AILIM |
| 12/16/2008 | US7465443 Acellular antibordetella vaccine |
| 12/16/2008 | US7465441 Using interleukins, immunoglobulin fusion; genetic engineering; signaling |
| 12/16/2008 | US7465440 Graft polymer of vinyl ester and polyether |
| 12/16/2008 | US7465438 Solubilizing agents/solvents for organic UV filters |
| 12/16/2008 | US7465437 Delivery of anti-migraine compounds through an inhalation route |
| 12/16/2008 | US7465436 Aerosol for delivery of benzotropine, pergolide, amantadine, deprenyl, or ropinerole, formed by vaporizing the drug that is coated on a solid support and condensing the vapor to form particles containing least 10 % by weight of the drug and less than 5 % by weight of degradation products |
| 12/16/2008 | US7465435 Delivery of beta-blockers through an inhalation route |
| 12/16/2008 | CA2505780C Transdermal administration of (r)-3,3-diphenylpropylamine monoesters |
| 12/16/2008 | CA2399377C New positive allosteric ampa receptor modulators (paarm), processes for preparing them and their use as pharmaceutical compositions |
| 12/16/2008 | CA2398887C 2,4,di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents |
| 12/16/2008 | CA2395129C Process for producing nanometer particles by fluid bed spray-drying |
| 12/16/2008 | CA2369739C Compositions and methods for improving integrity of compromised body passageways and cavities |
| 12/16/2008 | CA2367020C Method for producing solid dosage forms containing cyclodextrin |
| 12/16/2008 | CA2339835C Use of estrogenic compounds as anti-fungal agents |
| 12/16/2008 | CA2328411C Glucocorticoid receptor antagonists for the treatment of dementia |
| 12/16/2008 | CA2295519C A preparation derived from shark cartilage for treatment of diseases related to excessive phf or excessive intracellular calcium |
| 12/16/2008 | CA2294913C Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative |
| 12/16/2008 | CA2285817C Novel basic derivatives of benz[e]isoindol-1-ones and pyrrolo[3,4-c] quinolin-1-ones with 5-ht3-antagonistic activity, their preparation and their therapeutic use |
| 12/16/2008 | CA2285242C Mixture of primary fatty acids obtained from sugar cane wax |
| 12/16/2008 | CA2268099C Screening methods for glucocorticoid receptor binding substances using tripterygium wilfordii preparations |
| 12/16/2008 | CA2254975C Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells |
| 12/16/2008 | CA2253632C Compositions and methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna |
| 12/16/2008 | CA2239692C Diagnosis and treatment of aur-1 and/or aur-2 related disorders |
| 12/16/2008 | CA2133885C Crystalline inclusion complex of diclofenac with beta-cyclodextrin |
| 12/12/2008 | CA2634786A1 Production of glucosinolates from agricultural by-products and waste |
| 12/12/2008 | CA2634785A1 Enteric-coated glucosinolates and beta-thioglucosidases |
| 12/12/2008 | CA2591315A1 Method for treatment of depression and depressive mood disorders |
| 12/11/2008 | WO2008151323A1 Mixed lineage kinases and metabolic disorders |
| 12/11/2008 | WO2008151304A1 Selective inhibitors for cyclin-dependent kinases |
| 12/11/2008 | WO2008151303A1 Long wavelength fluorogenic intercellular ion indicators |
| 12/11/2008 | WO2008151288A2 Aromatic and heteroaromatic compounds useful in treating iron disorders |
| 12/11/2008 | WO2008151253A1 Hypoxia activated prodrugs of antineoplastic agents |
| 12/11/2008 | WO2008151249A2 Enteric coated, soluble creatine and polyethylene glycol composition for enhanced skeletal uptake of oral creatine |
| 12/11/2008 | WO2008151211A1 Substituted benzoylamino-indan-2-carboxylic acids and related compounds |
| 12/11/2008 | WO2008151184A1 Benzamide mglur5 positive allosteric modulators and methods of making and using same |
| 12/11/2008 | WO2008151170A2 Process for the synthesis of ramelteon and its intermediates |
| 12/11/2008 | WO2008151073A1 Compounds and methods for the diagnosis and treatment of amyloid associated diseases |
| 12/11/2008 | WO2008151035A2 Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (mds) |
| 12/11/2008 | WO2008151024A1 Protein kinase-binding nucleosides and associated methods |
| 12/11/2008 | WO2008151019A1 Extended release of bioactive molecules from silicone hydrogels |
| 12/11/2008 | WO2008150957A2 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles |
| 12/11/2008 | WO2008150954A1 Treatment of age-related macular degeneration |
| 12/11/2008 | WO2008150914A1 Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators |
| 12/11/2008 | WO2008150899A1 Combination therapies for treatment of cancer and inflammatory diseases |
| 12/11/2008 | WO2008150868A1 Methods for inducing therapeutic t cells for immune diseases |
| 12/11/2008 | WO2008150848A1 Antidepressant heteroaryl derivatives of heterocycle-fused benzodioxans |
| 12/11/2008 | WO2008150845A1 Screening for wnt pathway modulators and pyrvinium for the treatment of cance |
| 12/11/2008 | WO2008150837A1 Methods of treatment |
| 12/11/2008 | WO2008150830A2 Metal complexes incorporated within biodegradable nanoparticles and their use |
| 12/11/2008 | WO2008150827A1 Naphthyridine, derivatives as p13 kinase inhibitors |
| 12/11/2008 | WO2008150799A1 Imidazopyridine kinase inhibitors |
| 12/11/2008 | WO2008150788A1 Polymers with bio-functional self assembling monolayer endgroups for therapeutic applications and blood filtration |
| 12/11/2008 | WO2008150782A1 Use of hdac inhibitors for the treatment of bone destruction |
| 12/11/2008 | WO2008150729A2 N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| 12/11/2008 | WO2008150565A2 Ranolazine for elevated brain-type natriuretic peptide |
| 12/11/2008 | WO2008150547A1 Pregnancy hormone combination for treatment of autoimmune diseases |
| 12/11/2008 | WO2008150532A1 Methods and compositions for treating recurrent cancer |
| 12/11/2008 | WO2008150528A1 Novel methods |
| 12/11/2008 | WO2008150526A1 Tamper resistant lipid-based oral dosage form for opioid agonists |
| 12/11/2008 | WO2008150505A1 Compounds, polymers and methods for treating gastrointestinal dysfunction |
| 12/11/2008 | WO2008150495A2 Vwf aptamer formulations and methods for use |
| 12/11/2008 | WO2008150493A1 Pharmaceutical composition comprising a substrate and a coating containing an active ingredient and polyvinylalcohol |
| 12/11/2008 | WO2008150492A1 Tricyclic inhibitors of fatty acid amide hydrolase |
| 12/11/2008 | WO2008150486A2 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| 12/11/2008 | WO2008150480A1 Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| 12/11/2008 | WO2008150477A2 N-acetyl mannosamine as a therapeutic agent |
| 12/11/2008 | WO2008150470A1 Oxyimino compounds and the use thereof |
| 12/11/2008 | WO2008150447A1 Amide compounds and the use thereof |
| 12/11/2008 | WO2008150446A1 Inhibitors of protein kinases |
| 12/11/2008 | WO2008150439A1 Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use |
| 12/11/2008 | WO2008150438A1 Pmea lipid conjugates |
| 12/11/2008 | WO2008150388A1 Inhibiton of mitochnodrial uncoupling protein |
| 12/11/2008 | WO2008150364A1 Cyclopropyl pyrrolidine orexin receptor antagonists |
| 12/11/2008 | WO2008150324A1 Subanalgesic doses of drug combinations |
| 12/11/2008 | WO2008150302A1 Treatment of neurofibromatosis with radicicol and its derivatives |
| 12/11/2008 | WO2008150260A1 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents |
| 12/11/2008 | WO2008150245A2 Stable formulation of amorphous perindopril salts, a process for the preparation thereof on industrial scale and use thereof in the treatment of hypertension |
| 12/11/2008 | WO2008150233A1 Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842 |
| 12/11/2008 | WO2008150232A1 Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators - 841 |
| 12/11/2008 | WO2008150231A1 New heterocyclic compounds for treatment of respiratory, airway or inflammatory disorders |
| 12/11/2008 | WO2008150217A1 2-amino-5, 5-diaryl-imidazol-4-one analogs for the inhibition of beta-secretase |
| 12/11/2008 | WO2008150197A1 Biologically active additive for preventing and treating asthma and diseases of the upper air passages and a method for the production thereof |
| 12/11/2008 | WO2008150191A1 Anorexigenic medicinal agent for controlling the body mass |
| 12/11/2008 | WO2008150190A1 Compositions based on 2,6-di-tert-buthyl-4-methylphenol and a method for treating firearm wounds with the aid of said compositions |
| 12/11/2008 | WO2008150074A2 The composition comprising the extracts, fractions and the isolated compounds of rhus verniciflua for prevention and treatment of diabetic complications |
| 12/11/2008 | WO2008150015A1 Heterobicyclic compounds as kinase inhibitors |